Poseida Therapeutics’ (PSTX) “Buy” Rating Reiterated at HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $20.00 price objective on the stock.

Poseida Therapeutics Stock Up 0.2 %

PSTX stock opened at $2.16 on Monday. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $208.42 million, a PE ratio of -1.55 and a beta of 0.36. Poseida Therapeutics has a twelve month low of $1.54 and a twelve month high of $4.27. The stock has a 50-day simple moving average of $3.13 and a two-hundred day simple moving average of $2.94.

Poseida Therapeutics (NASDAQ:PSTX) last posted its earnings results on Thursday, March 7th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. The business had revenue of $25.00 million during the quarter, compared to analyst estimates of $12.50 million. Poseida Therapeutics had a negative return on equity of 94.90% and a negative net margin of 190.76%. On average, equities analysts predict that Poseida Therapeutics will post -1.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd purchased a new position in shares of Poseida Therapeutics during the fourth quarter worth about $36,000. Tower Research Capital LLC TRC grew its holdings in shares of Poseida Therapeutics by 110.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock worth $36,000 after purchasing an additional 5,606 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Poseida Therapeutics during the third quarter worth about $29,000. Keystone Financial Group purchased a new position in shares of Poseida Therapeutics during the third quarter worth about $36,000. Finally, Strs Ohio purchased a new position in shares of Poseida Therapeutics during the third quarter worth about $47,000. Hedge funds and other institutional investors own 46.87% of the company’s stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.